Yale Cancer Center | Strategic Alliance Partners

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.

The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.

Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.

The addition of smoking status to the National Cancer Database might inform more effective treatment for smokers with cancer.

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

CURE® spoke with experts about what life is like for patients with cancer when their disease is in remission.

One researcher explains the science behind Lymphir, recently approved by the FDA for relapsed/refractory cutaneous T-cell lymphoma.

Imdelltra has offered a new treatment option for patients with small cell lung cancer that “is not like anything we’ve ever seen before,” an expert said.

In collaboration with the Kidney Cancer Association, CURE® recently hosted the “Educated Patient® Webinar: Treating the Whole Patient: Navigating Kidney Cancer,” hosted by Darlene Dobkowski, Associate Editorial Director for CURE®.